following a full submission:
upadacitinib (Rinvoq®) is accepted for restricted use within NHSScotland.
Indication under review: for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.
SMC restriction: patients who have had an inadequate response to at least one conventional systemic immunosuppressant such as ciclosporin, or in whom such treatment is considered unsuitable.
In patients with moderate to severe atopic dermatitis eligible for systemic therapy, upadacitinib was associated with significantly greater improvements in the signs and symptoms of atopic dermatitis in adults and adolescent patients in three placebo-controlled phase III studies and in adult patients in one phase III comparative study with a monoclonal antibody.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/list price that is equivalent or lower.
- Medicine name:
- upadacitinib (Rinvoq)
- SMC ID:
Treatment of moderate to severe atopic dermatitis (AD) in adults and adolescents 12 years and older who are candidates for systemic therapy.
- Pharmaceutical company
- AbbVie Ltd
- Submission type
- Date advice published
- 11 April 2022